Clinical trials: Chronic Obstruct Airways Disease
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5.
- Trial name
- STRENGTH (NCT06678191)
- Testing
- BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
- Where
- 45 sites in Hungary
- Volunteers
- 800 people
- Sponsor
- Chiesi Hungary Ltd.
COPD, Comorbidities and Coexisting Conditions
Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease
This is a 12 month study of up to 500 people with COPD to determine if the NuvoAir clinical service leads to lower rates of severe COPD exacerbations, hospitalizations, emergency room visits, and total cost of care compared to a…
- Trial name
- PROMISE (NCT05955482)
- Testing
- NuvoAir Clinical Service
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NuvoAir Medical PC
Comparative Effectiveness Study
Treatment and Exacerbation in COPD Subjects
This is a study comparing the effects of ICS containing treatments in patients with chronic obstructive pulmonary disease (COPD) in a real world setting, using the UK Clinical Practice Research Datalink (CPRD) linked with…
- Trial name
- NCT03375450
- Testing
- Standard of Care
- Where
- United Kingdom
- Volunteers
- 60,243 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
CorRELation Between PatIent PErception and Findings on Clinical Examination
This is a multi-center, prospective, non-interventional study that aims to evaluate in daily clinical practice, the possible corelation between patIent perception of the ability to perform morning activities and physician…
- Trial name
- RELIEF (NCT01627743)
- Where
- 19 sites in Romania
- Volunteers
- 505 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects
This is a dose escalation trial. The dosing regimen involves a single-dose study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetic…
- Trial name
- NCT06408285
- Testing
- TQC3927 powder for inhalation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while…
- Trial name
- ENHANCE-3 (NCT07874815)
- Testing
- Ensifentrine, Standard of Care (SOC)
- Volunteers
- 2,136 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT06944925
- Testing
- BBT002
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
- Trial name
- NCT06603246
- Testing
- GDC-6988
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Genentech, Inc.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patients with COPD
- Trial name
- NCT00581945
- Testing
- Canakinumab
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI 1744 CL.
- Trial name
- NCT01809262
- Testing
- single dose of 5 mcg, single dose of 40 mcg, single dose of 20 mcg
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00624286
- Testing
- Indacaterol 150 μg
- Where
- 120 sites in United States, Belgium and 1 more
- Volunteers
- 416 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® [tiotropium] given as 18 mcg…
- Trial name
- GOLDEN-5 (NCT02276222)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
- Where
- 118 sites in United States, Czechia and 2 more
- Volunteers
- 1,087 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Lung Disease
Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).
This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with…
- Trial name
- SORT-COPD (NCT06986070)
- Testing
- Stem cells
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- SMSbiotech
Lung Diseases, Bronchitis, Chronic
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of…
- Trial name
- NCT00473460
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 78 sites in United States, Andorra and 13 more
- Volunteers
- 1,404 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a phase IIIa, randomised, double-blind, double-dummy, parallel group multicenter study evaluating once daily FF/UMEC/VI (100 microgram [mcg]/62.5 mcg/25 mcg) inhalation powder versus twice daily budesonide/formoterol (400…
- Trial name
- NCT02345161
- Testing
- Triple FF/UMEC/VI, Budesonide/Formoterol, Albuterol/salbutamol
- Where
- 159 sites in Bulgaria, China and 13 more
- Volunteers
- 1,811 people
- Sponsor
- GlaxoSmithKline
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
- Trial name
- NCT07116889
- Testing
- GB-0895 (SC)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Generate Biomedicines
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea…
- Trial name
- NCT00662740
- Testing
- FDC tiotropium / salmeterol, Salmeterol, Tiotropium (Spiriva®)
- Where
- 72 sites in United States, Austria and 16 more
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the safety and preliminary performance of the ROX Anastomotic Coupler System (ACS), with standard of care (as defined per GOLD) in patients with Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT00992680
- Testing
- ROX Anastomotic Coupler System (ACS)
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- ROX Medical, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.